Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Essentia Health-Hayward Clinic — Hayward, Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- University of Wisconsin Carbone Cancer Center - Johnson Creek — Johnson Creek, Wisconsin
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Wisconsin: - Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Wisconsin: - Research Site — Madison, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Wisconsin: - SSM Health Dean Medical Group ( Site 0140) — Madison, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Wisconsin: - Gunderson Health System — La Crosse, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research — Madison, Wisconsin
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in Wisconsin: - Prohealth Care Inc — Waukesha, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Wisconsin: - Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- Cancer Center of Western Wisconsin — New Richmond, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Wisconsin: - Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
- Marshfield Medical Center-Rice Lake — Rice Lake, Wisconsin
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Wisconsin: - Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Wisconsin: - SSM Health Dean Medical Group ( Site 0106) — Madison, Wisconsin
- Medical College of Wisconsin ( Site 0103) — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a si…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06090539
Sites in Wisconsin: - Local Institution - 0024 — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-el…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT04626791
Sites in Wisconsin: - Aurora Cancer Care-Milwaukee West — Wauwatosa, Wisconsin
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of…
Sponsor: Reid Merryman, MD
NCT ID: NCT05783609
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significan…
Sponsor: Mayo Clinic
NCT ID: NCT03418038
Sites in Wisconsin: - Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
- Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04609046
Sites in Wisconsin: - Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
- Marshfield Medical Center-Rice Lake — Rice Lake, Wisconsin
Phase 1 Recruiting Industry
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Sponsor: Caribou Biosciences, Inc.
NCT ID: NCT04637763
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…
Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Academic/Other
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…
Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin